Mineralys Therapeutics, Inc. MLYS R2K
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -139.7% CAGR over 5 years.
- Trading 33.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MLYS Mineralys Therapeutics, Inc. R2K | 31.50 | - | $2.60B | - | -26.38% | -30.99% | - | -139.66% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 44.45M | 46.75M | 41.13M | 38.28M | 45.34M |
| Operating Income | -7.57M | -6.48M | -7.42M | -14.94M | -15.73M | -26.27M | -35.36M | -45.17M | -60.11M | - | -44.45M | -46.75M | -41.13M | -38.28M | -45.34M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -44.43M | -46.73M | -41.12M | -38.27M | -45.33M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -42.21M | -43.27M | -36.93M | -32.23M | -39.34M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -7.57M | -6.48M | -6.68M | -12.61M | -12.14M | -22.76M | -31.51M | -41.01M | -56.34M | - | -42.21M | -43.27M | -36.93M | -32.23M | -39.34M |
| Diluted EPS | -1.48 | -1.26 | -1.29 | -0.51 | -0.31 | -0.57 | -0.70 | -0.83 | -1.13 | - | -0.79 | -0.66 | -0.52 | -0.40 | -0.47 |
| R&D Expense | 6.78M | 5.59M | 6.06M | 12.29M | 11.88M | 22.50M | 30.75M | 39.27M | 53.98M | - | 37.88M | 38.28M | 31.45M | - | 24.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 31.48M | 84.66M | 192.40M | 170.60M |
| Operating Income | - | -31.48M | -84.66M | -192.40M | -170.60M |
| EBITDA | - | -31.48M | -84.66M | -192.36M | -170.54M |
| Interest Expense | 27.00K | - | - | - | - |
| Pretax Income | - | -29.80M | -71.90M | -177.81M | -154.65M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -29.80M | -71.90M | -177.81M | -154.65M |
| Diluted EPS | -3.77 | -0.76 | -1.99 | -3.66 | - |
| R&D Expense | - | 26.25M | 70.36M | 168.58M | 132.01M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -139.66% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +102.18% |
| 6 Months: | -25.36% |
| 3 Months: | +7.66% |
| 1 Month: | +23.24% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 114.44M | 251.64M | 205.90M | 661.81M |
| Current Assets | - | 112.81M | 249.10M | 205.35M | 661.39M |
| Cash & Equivalents | - | 87.70M | 49.30M | 114.09M | 172.92M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 166.71M | 10.48M | 14.65M | 15.11M |
| Current Liabilities | - | 8.07M | 10.48M | 14.65M | 15.11M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
| Total Equity | - | -52.27M | 241.15M | 191.26M | 646.69M |
| Shares Outstanding | - | 39.06M | 41.13M | 49.82M | 81.54M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -29.22M | -81.17M | -166.31M | -142.42M |
| Investing Cash Flow | - | -21.76M | -160.47M | 114.96M | -389.75M |
| Financing Cash Flow | - | 128.02M | 203.25M | 116.14M | 591.00M |
| Capital Expenditure | - | - | - | -96.00K | -15.00K |
| Free Cash Flow | - | -29.22M | -81.17M | -166.41M | -142.43M |
| Net Change in Cash | - | 77.04M | -38.40M | 64.79M | 58.83M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 57.0% | -29.8% | -93.0% | -23.9% |
| ROCE % | - | -29.6% | -35.1% | -100.6% | -26.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Catalys Pacific, LLC | 9.58% | 7.90M | $248.97M |
| 2 | RA Capital Management, L.P. | 9.32% | 7.69M | $242.32M |
| 3 | Samsara BioCapital, LLC | 7.12% | 5.87M | $184.94M |
| 4 | FMR, LLC | 5.89% | 4.86M | $153.12M |
| 5 | Blackrock Inc. | 5.43% | 4.48M | $141.17M |
| 6 | Wellington Management Group, LLP | 4.07% | 3.36M | $105.81M |
| 7 | State Street Corporation | 3.56% | 2.94M | $92.48M |
| 8 | Caligan Partners, LP | 3.36% | 2.77M | $87.34M |
| 9 | Vanguard Capital Management LLC | 2.98% | 2.45M | $77.31M |
| 10 | Laurion Capital Management, LP | 2.71% | 2.23M | $70.31M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MLYS